- Top of page
- MATERIALS AND METHODS
- CONFLICT OF INTEREST
- Supporting Information
Acute urinary retention is a severe symptom of men with BPH. It is defined as a sudden and painful inability to void voluntarily [1,2]. Although the causes of AUR are variable, BPH accounts for most episodes. The prevalence rate of AUR in men with BPH is estimated to be as high as 53% . AUR is not only painful, but also the harbinger of severe systemic diseases. Higher mortality and morbidity rates in men presenting with AUR have been reported in previous studies [4,5].
In Western countries, AUR was the chief compliant in 20–42% of men who underwent TURP . Escalating postoperative complications and longer hospital stays in men with BPH who develop AUR have been reported [5–7]. Patients who presented with AUR had a high mortality rate in the first 3 years after prostatectomy .
Most of the AUR-related complications reported in previous studies, however, were not primary endpoints in their study settings. Comprehensive comparisons of post-TURP complications between patients with and without AUR are lacking. Furthermore, these studies did not prove that patients given elective TURP did not have a history of AUR. The present population-based study provides a general view on the differences of post-TURP complications between patients with AUR (AUR+) and those without (AUR-) in Taiwan.
- Top of page
- MATERIALS AND METHODS
- CONFLICT OF INTEREST
- Supporting Information
From the NHIRD, we identified 331 188 men who had a BPH diagnosis between 1 January 2002 and 31 December 2004. Approximately 3.3% of them (n= 11 036) underwent TURP. Patients with prostate cancer (n= 402), Parkinsonism (n= 87) and multiple sclerosis (n= 1) were excluded. In addition, 6179 men were excluded because they did not fit the criteria of the definition of AUR or meet the event sequence. Finally, 3305 patients (mean [sd] age 72.3 [8.0] years) were included in the AUR+ group, and 1062 patients (mean [sd] age: 70.4 [7.8] years) without any AUR episodes in the AUR- group (Table 1). In the AUR+ group, 2373 patients (71.8%) underwent TURP < 1 month after an AUR episode, and 2618 patients (79.2%) < 3 months after an AUR episode.
Table 1. Demographic data of the AUR+ and AUR- groups
|Variable||AUR+ group, N= 3305||AUR- group, N= 1062|| P |
|Mean (sd; range), years||72.3 (8.0; 50–94)||70.4 (7.8; 50–97)||0.648|
|Mean no. of AUR episodes||2.6||0||NA|
|Mean (sd) CCI score||2.9 (2.5)||2.5 (2.1)||<0.001|
|Age distribution, years, n (%)|| || ||<0.001|
|50–59||219 (6.6)||85 (8.0)|
|60–69||935 (28.3)||387 (36.4)|
|70–79||1539 (46.6)||471 (44.4)|
|80–89||574 (17.4)||115 (10.8)|
|≥90||38 (1.1)||4 (0.4)|
There were no post-TURP Foley catheterizations in the AUR- group (Table 2). In the AUR+ group, the mean episodes of preoperative AUR were 2.6 (Table 1). A total of 13.8% of patients in the AUR+ group needed to be re-catheterized after surgery (Table 2). In this subgroup of patients, the mean episodes of preoperative AUR were 4.0, higher than that of the AUR+ group as a whole.
Table 2. Comparison of complications between the AUR+ and AUR−− groups
|Variables||AUR+ group, N= 3305||AUR- group N= 1062||OR|| P |
|Foley, n (%)||457 (13.8)||0||NA||<0.001|
|Haematuria||269 (8.1)||79 (7.4)||1.10 (0.85–1.43)||0.46|
|UTI||626 (18.9)||166 (15.6)||1.26 (1.05–1.52)||0.01|
|Lower urinary tract stricture||87 (2.6)||34 (3.2)||0.82 (0.55–1.22)||0.32|
|Urethral||29 (33.3)||16 (47.1)|
|Bladder neck||56 (64.4)||18 (52.9)|
|Re-surgery of prostate||33 (1.0)||14 (1.3)||0.76 (0.40–1.42)||0.38|
|LUTS||754 (22.8)||180 (16.9)||1.45 (1.21–1.73)||<0.001|
|Incontinence||244 (7.4||82 (7.7)|
|Frequency||300 (9.1)||68 (6.4)|
|Dysuria||201 (6.1)||28 (2.6)|
|Other*||9 (0.3)||2 (0.2)|
|Blood transfusion||107 (3.2)||16 (1.5)||2.19 (1.29–3.72)||0.004|
|Antibiotics||29 (0.9)||7 (0.7)||1.33 (0.58–3.05)||0.49|
|Mean (sd) length of hospital stay, days||6.4 (7.2)||4.6 (2.0)|| ||<0.001|
|Mean (sd) medical expense||44 677.5 (32 690.3)||38 070.0 (8567.1)|| ||<0.001|
The differences in haematuria < 2 weeks after TURP were not significant. Preoperative anticoagulant use in the AUR+ and AUR- groups was examined. The correlation in each group between anticoagulant use and postoperative haematuria was not significantly different between the groups (Table 3). The rate of postoperative UTI was higher in the AUR+ group (18.9% vs. 15.6%, P= 0.01; OR: 1.26, 95% CI 1.05–1.52). No patients in the AUR- group had a preoperative UTI; however, 805 patients (24.4%) in the AUR+ group had preoperative UTIs, and 161 patients had postoperative UTIs. Of 2500 patients without preoperative UTIs, 469 (18.8%) developed postoperative UTIs. The null hypothesis could not be excluded (P= 0.44). This result suggested a greater number of ascending UTIs in men with Foley catheterization.
Table 3. Anticoagulant use among patients with haematuria and patients given blood transfusions
|Group||Anticoagulant use (+), n||Anticoagulant use (−), n|| P |
|Haematuria (−)||409||2625|| |
|Blood transfusion (+)||20||87||0.14|
|Blood transfusion (−)||432||2766|| |
|Haematuria (−)||105||878|| |
|Blood transfusion (+)||4||15||0.16|
|Blood transfusion (−)||113||930|| |
The rates of both lower urinary tract stricture (2.6% vs. 3.2%, P= 0.32) and prostate re-operation (1.0% vs. 1.3%, P= 0.38) were slightly lower in the AUR+ group than in the AUR- group. Postoperative LUTS were more prevalent in the AUR+ group than in the AUR- group (22.8% vs. 16.9%, OR = 1.45, 95% CI: 1.21–01.73). In both groups, incontinence and frequency accounted for >70% of LUTS. In the AUR+ group, frequency was the most common lower urinary tract symptom (39.8%), while in the AUR- group, incontinence was (45.6%).
Septicaemia (1.1%) and shock (0.3%) during hospitalization occurred only in the AUR+ group. The blood transfusion rate was twice as high in the AUR+ group as in the AUR- group (3.2% vs. 1.5%, OR = 2.19, 95% CI: 1.29–3.72). Preoperative anticoagulant use had no significant effect on blood transfusion (Table 3), nor was there a significant difference in the use of second-line antibiotics. The mean (sd) length of hospital stay was 6.4 (7.2) days in the AUR+ group and 4.6 (2.0) days in the AUR- group (P < 0.001), and medical expenses were New Taiwan dollars (NT$) 44 677.5 (32 690.3) in the AUR+ group and NT$38 070.0 (8567.1) in the AUR- group (P < 0.001), which suggested more in-hospital complications in the AUR+ group.
Univariate analysis showed that age, hospitalization stays (regardless of whether or not the patient had AUR, and CCI score were all significantly correlated with medical expenses (Table 4). The mean medical expense was NT$6607.5 higher in the AUR+ group than in the AUR- group. In multivariate analysis, the length of hospital stay and the CCI score remained significant.
Table 4. Univariate and multivariate analysis of medical expenses
|B estimate|| P ||B estimate|| P |
|Length of hospital stay||3215.2||<0.001||3182.7||<0.001|
|Group (AUR+ or AUR-)||6607.5||<0.001||487.7||0.502|
Both the univariate and multivariate analysis (Table 5) showed that the group factor was associated with re-catheterization and postoperative UTI. For the lower urinary tract stricture and second-line antibiotics, the group factor was more persuasive than CCI score factor in multivariate analysis. Septicaemia, shock, blood transfusion, length of hospital stay and LUTS were all correlated with group factors and CCI score, but in group factors especially, the ORs were much higher.
Table 5. Univariate and multivariate analysis of complications
|Variables||Group (AUR+ or AUR-)|
|OR (95%CI)|| P ||OR (95%CI)|| P |
|Haematuria||1.10 (0.85–1.43)||0.46||1.17 (0.90–1.52)||0.24|
|UTI||1.26 (1.05–1.52)||0.01||1.63 (1.35–1.98)||<0.001|
|Lower urinary tract stricture||0.82 (0.55–1.22)||0.32||0.54 (0.30–0.99)||0.05|
|Re-surgery of prostate||0.76 (0.40–1.42)||0.38||0.71 (0.37–1.33)||0.29|
|LUTS||1.45 (1.21–1.73)||<0.001||1.40 (1.15–1.69)||0.001|
|Blood transfusion||2.19 (1.29–3.72)||0.004||1.92 (1.13–3.27)||0.02|
|Antibiotics||1.33 (0.58–3.05)||0.49||8.14 (1.1–60.0)||0.04|
|Hospitalization|| ||<0.001|| ||<0.001|
| Variables || CCI score |
| Univariate || Multivariate |
| OR (95%CI) || P || OR (95%CI) || P |
|Foley||1.03 (0.99–1.08)||0.10||1.02 (0.98–1.06)||0.44|
|Haematuria||0.98 (0.94–1.03)||0.40||0.99 (0.94–1.03)||0.57|
|UTI||0.98 (0.95–1.01)||0.25||0.99 (0.95–1.02)||0.41|
|Lower urinary tract stricture||1.07 (1.00–1.15)||0.05||0.19 (0.97–1.20)||0.19|
|Re-surgery of prostate||1.12 (1.01–1.23)||0.03||1.12 (1.01–1.24)||0.03|
|LUTS||1.04 (1.01–1.07)||0.02||1.04 (1.01–1.07)||0.02|
|Septicaemia||1.32 (1.19–1.47)||<0.001||1.33 (1.19–1.48)||<0.001|
|Shock||1.27 (1.06–1.51)||0.01||1.23 (1.02–1.47)||0.03|
|Blood transfusion||1.11 (1.04–1.18)||0.002||1.08 (1.00–1.15)||0.03|
|Antibiotics||1.16 (1.03–1.3)||0.02||1.12 (1.00–1.27)||0.06|
|Length of hospital stay|| ||<0.001|| ||<0.001|
- Top of page
- MATERIALS AND METHODS
- CONFLICT OF INTEREST
- Supporting Information
To our knowledge, this is the first large-scale population-based cohort study in Asia to compare AUR complications after TURP. To avoid possible confounding factors, we excluded patients diagnosed with prostate cancer, Parkinsonism, and multiple sclerosis. Only men meeting the AUR criteria were included. CCI score, preoperative anticoagulant use, and UTIs were investigated and analysed using a chi-squared test. We found that re-catheterization, in-hospital septicaemia and shock occurred only in the AUR+ group. Patients in the AUR+ group developed more postoperative UTIs and LUTS, needed more blood transfusions, had longer hospital stays, and had higher medical expenses than did patients in the AUR- group. We thus inferred that patients with BPH with AUR have a higher risk of complications after TURP.
In the present study, 32.6% of the patients had AUR before TURP. According to earlier studies, AUR accounted for 27%, 23%, and 43% of all patients with BPH undergoing prostatectomy in North America, the UK and Singapore, respectively [5,6,13]. In the Singapore report, the trend declined decennially from 79 to 43%. The decreasing rate may be attributed to the advancement of medical therapy or early surgical interventions.
Interestingly, we also found that no one in the AUR- group had been re-catheterized after surgery. This finding suggested that the detrusor contractile function of men with AUR might have been injured after urinary retention . In earlier studies, the reported failure to void rate after TURP ranged from 3.0 to 12% [5,15–20]. The present findings suggested a higher rate. A possible explanation is that most previous studies did not separate patients into AUR+ and AUR- groups. The present study showed there was a tendency for re-catheterization after TURP in patients in the AUR+ group. These patients should be informed about the possibility of re-catheterization after TURP.
The postoperative haematuria rate was slightly higher in the AUR+ group, but not significantly so. Elevated postoperative UTIs and re-catheterization rate in the AUR+ group may delay wound healing and make the tissue more fragile. The haemostasis procedure may also affect the result. Preoperative anticoagulant use was not associated with haematuria. We inferred that most surgeons would suggest that patients stop anticoagulant use 7 days before TURP to avoid surgical bleeding. In addition, because our data came from the NHIRD, we were unable to examine the patients' drug compliance.
The postoperative UTI rate in the AUR+ group was 18.9%, higher than in the AUR- group. In Pickard et al. , the total urinary infection rate (including suspected and proved UTI, and epididymo-orchitis) was 18.6%. Nonetheless, the overall post-TURP UTI rate reported in the literature was <5%, except for 25% in Doll et al. . Both Pickard et al.  and the present study found more prevalent infection events in the AUR+ group. The reason for this discrepancy may be different study definitions of UTI. The NHIRD was established as an administrative tool; detailed clinical laboratory data, such as urine analyses and cultures, were not available for the present study. In addition, a higher re-catheterization rate in the AUR+ group may have led to a greater prevalence of ascending UTIs.
In the literature , the urethral stricture rate ranges from 2.2 to 9.8% and the bladder neck stricture rate from 0.3 to 9.2%. In the present study, the lower urinary tract stricture rates in the two groups were ∼3%. Theoretically, more Foley catheterizations and the greater number of UTIs in the AUR+ group would lead to a higher urinary tract stricture rate, but there were no differences in lower urinary tract stricture rates between the two groups. Surgical technique, choice of instrument size, and sufficient or insufficient lubricant may all account for the background biases . TURP was a definitive treatment for BPH. The retreatment rate of TURP has been reported to be 3–14.5% after 5 years . In the present study, the mean time before re-surgery of the prostate was 62 days in the AUR+ group and 81 days in the AUR- group (data not shown). Reasons for an early return to the operation room included a blood clot tamponade, uncontrolled bleeding, or an insufficient resection. There was no significant difference in the re-surgery rate between the two groups, but the AUR+ group returned to the operation room earlier than the AUR- group.
In the present study, there were a greater number of LUTS complaints in the AUR+ group. These complaints were subjective. In addition to vesical aetiology, the greater number of postoperative re-catheterizations and UTI episodes in the AUR+ group may explain the discrepancy between the two groups. Incontinence rates were reported as 0.3% in Haupt et al. , 1.0% in Kuntz et al. , and 38% in Doll et al. . The different definition of LUTS used in the present study may account for the discrepancy between incontinence rates and the aforementioned studies. The present study included not only incontinence, but also frequency, dysuria, and others (e.g. splitting of urinary stream and slowing of urinary stream). Although the IPSS has provided a reliable tool for assessing LUTS, the information needed was not available in the NHIRD. Although LUTS were common during the early postoperative period, one study  followed-up the IPSS 1 year after TURP and discovered that the IPSS gradually decreased (improved) from 25 to 4 points. Obviously, the AUR had some impact on urinary bladder function or perception. Although it was not a lethal condition, it contributed to a deterioration in quality of life.
In the present study, there were more in-hospital complications in the AUR+ group, including septicaemia, shock, second-line antibiotic use and blood transfusions. The first two events did not even occur in the AUR- group, and the incidence rates were not higher than in previous reports. The blood transfusion rate in the AUR+ group was twice that in the AUR- group. The larger prostate in AUR+ men may explain that difference. Prostatic infarction may also have been associated with it. Prostatic infarction has long been suspected to be one of the aetiologies of AUR [23,24]. Post-infarction fragile vessel integrity may lead to much more postoperative bleeding. Further histopathological study may help to clarify whether there is an association. Finally, the longer hospital days and higher medical expenses both suggested a more complicated course of hospitalization for the AUR+ group. The greater comorbidity in AUR+ group patients was associated with higher medical expenses both in univariate and in multivariate analysis. Thus, we suggest that BPH patients with AUR should be treated as a special group. A preoperative warning and multidisciplinary medical care are warranted for these patients.
The present study has some limitations. First, the NHIRD lacked some clinical information, such as prostate size and IPSS, which is a universal methodological limitation when using administrative databases; however, BPH is a clinical diagnosis and the symptoms may not always be proportional to prostate size. For most patients, the obstructive symptoms were resolved after TURP. Most patients complained of irritating symptoms, such as incontinence and urinary frequency and these patients would have higher IPSS scores. Second, the effect on AUR of medications such as anticholinergics was not excluded in our study as we did not exclude patients taking these medications. This did not affect our results significantly; the incidence rate of medication related to AUR was as low as 2% [3,25]. In addition, most of the patients susceptible to the medication effect already had clinical BPH symptoms. Third, second-line antibiotics are prescribed only in the hospital and under strict regulations by the infection control centre of each hospital in Taiwan. We believe that the record of antibiotic use is accurate.
In conclusion, the present study is a real-world study reflecting current practice in Taiwan. Our findings support the hypothesis that BPH patients with AUR who undergo TURP are associated with a higher risk of complications than those without. Re-catheterization, postoperative UTIs, LUTS, septicaemia, shock, blood transfusions, second-line antibiotic use, hospitalization days, and medical expenses were all higher in the AUR group. The underlying mechanism of AUR on the post-TURP complications is not clear. Further pathophysiological studies are necessary to elucidate this. Preventing AUR secondary to BPH implies delaying the progression in patients at risk and improving the prognosis when they are given TURP. Once AUR develops, a preoperative warning and cautious postoperative care are warranted for these patients.